Profile: Oculus Innovative Sciences Inc (OCLS.OQ)
Oculus Innovative Sciences, Inc., incorporated on November 20, 2006, is a global healthcare company that designs, produces, and markets prescription and non-prescription products in over 20 countries.The Company’s focus is on the commercialization of its technology platform called Microcyn Technology. This technology is based on electrically charged oxychlorine small molecules designed to target a wide range of organisms that cause disease (pathogens). Outside the United States, its Microcyn Technology products have a CE Mark device approval in Europe for debriding, irrigating and moistening acute and chronic wounds in comprehensive wound treatment by reducing microbial load and creating a moist environment. In Mexico, it is approved as a drug for antiseptic. In India, the Company's technology has a drug license for cleaning and debriding in wound management. In China, it has obtained a medical device approval by the State Food and Drug Administration for reducing the propagation of microbes in wounds and creating a moist environment for wound healing.
Microcyn is a solution of oxychlorine compounds that, among other things, interact with and inactivate surface proteins on cell walls and membranes of microorganisms. The functions of these proteins are varied and play roles in cell communication, nutrient and waste transport and other required functions for cell viability. Once Microcyn surrounds single cell microorganisms, it damages these proteins, causing the cell membrane to rupture, to cell death, which is caused by increased membrane permeability and induced osmotic pressure imbalance. In laboratory tests, Microcyn has been shown to destroy certain biofilms. A biofilm is a complex cluster of microorganisms or bacteria marked by the formation of a protective shell, allowing the bacteria to collect and proliferate.
The Company has completed a proof-of-concept Phase II trial in the United States, which demonstrated the effectiveness of Microcyn Technology in mildly infected diabetic foot ulcers with the primary endpoint of clinical cure and improvement of infection. It used 15 clinical sites and enrolled 48 evaluable patients in three arms, using Microcyn alone, Microcyn plus an oral antibiotic and saline plus an oral antibiotic. In addition to the Phase II trial mentioned above, several physicians and scientists have completed more than 40 clinical and scientific studies of Microcyn Technology generating data suggesting that the technology is non-irritating to healthy tissue, reduces microbial load, accelerates wound healing, reduces pain, shortens treatment time and may have the potential to reduce costs to healthcare providers and patients. The Company has sponsored many of the physicians performing these studies by supplying Microcyn-based products, unrestricted research grants, paying expenses or providing honoraria.The studies were performed in the United States, Europe, India, Pakistan, China and Mexico, and used various endpoints, methods and controls, including saline, antiseptics and antibiotics.
The Company makes Microcyn-based human advanced wound and tissue care products available, both as prescription and over-the-counter products, under its seven 510(k) clearances in the United States, primarily through a combination of partnerships . The Company has announced the commercialization of a Microcyn product for advanced wound care sold through a contract sales force and by Eloquest Healthcare, and the commercialization of Microcyn products for dermatology through a partnership with Quinnova Pharmaceuticals. Through its healthcare products, designed specifically for the care of horses, dogs, cats, exotic pets and farm/ranch animals and branded as Vetericyn, in the United States and Europe. It is introducing Vetericyn- branded products into Canada and Asia.
The Company derives a portion of its revenues from its dermatology products, which are sold in partnership with Quinnova. Quinnova launched the AtraproTM family of products formulated from its Microcyn Technology platform. The products include: Atrapro Antipruritic Hydrogel, a non-oily, quick drying gel designed for the relief of pain, burning and itching associated with various dermatoses (pruritus), which may include the treatment of atopic dermatitis and radiation dermatitis; Atrapro Dermal Spray with Preservatives, a non-cytotoxic, non-irritating, and non-sensitizing spray for the management via debridement of wounds such as partial- and full-thickness wounds, post-surgical wounds, first- and second-degree burns, and grafted and donor site, and a kit for the treatment of various dermatoses which packages together Quinnova’s Neosalus Cream with Proderm Technology and Atrapro Antipruritic Hydrogel, a product based on its Microcyn Technology.
NVN Therapeutics is based out of Sacramento, California. This division is focused on the development of products for the diabetic and women’s health markets. In April 2012, the Company launched its nutritional product, Glucorein Green Tea with chlorogenic acid, a medical food intended for the dietary management of glucose levels in both pre-diabetics and type 2 diabetics under the supervision of a medical professional. Its product is being test-marketed in the United States and by medical professionals. Its second product, Glucorein PCOS, was launched in the women’s health market and is intended for the dietary management of Polycystic Ovary Syndrome (PCOS). PCOS afflicts approximately 10% of women of reproductive age and is thought to be one of the causes of female subfertility and the frequent endocrine problem in women of reproductive age.
The Company competes with Kinetic Concepts Inc., Smith & Nephew, Advanced BioHealing, Integra Life Sciences, Life Cell, Organogenesis, Ortec International and Celleration.
Oculus Innovative Sciences Inc
1129 North McDowell Blvd.
PETALUMA CA 94954